Skip to content

Clinical trials

Pulmonary Disease, Chronic Obstructive trials with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Disease, Chronic Obstructive Status: Unknown status Clear all

790 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20022
20033
20047
20054
20066
20079
200811
200928
201020
201138
201224
201327
201435
201539
201647
201763
201846
201976
202049
202174
202256
202385
202436
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status790

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assiut University16
Henan University of Traditional Chinese Medicine14
China-Japan Friendship Hospital12
Laval University10
KU Leuven9
Riphah International University9
Chinese Academy of Medical Sciences, Fuwai Hospital8
The First Affiliated Hospital of Guangzhou Medical University8
Universidad de Granada8
Guangzhou Institute of Respiratory Disease7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Disease, Chronic Obstructive790
Asthma68
Dyspnea34
Heart Failure34
Emphysema30
Diabetes Mellitus22
Lung Diseases, Interstitial19
Respiratory Insufficiency19
Bronchitis, Chronic17
Lung Diseases17

Trials

Showing 26 to 50 of 790. Each trial links to its page on Pharma Observatory.

690 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.